A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Investigate The Safety And Efficacy Of Multistem (Pf-05285401) In Subjects With Moderate To Severe Ulcerative Colitis

Trial Profile

A Phase 2 Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center Study To Investigate The Safety And Efficacy Of Multistem (Pf-05285401) In Subjects With Moderate To Severe Ulcerative Colitis

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Allogeneic stem cell therapy Athersys (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Apr 2014 Topline results were reported in an Athersys media release. 16-Week follow up results, including biomarker analyses, will be reported at a later date.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top